INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Results

20,923 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,101
300 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

Page 343 of 524
← PrevNext →
0
SE
Schubach Sarah ElizabethChief Accounting Officer
DBXDROPBOX, INC.
Open-market sale · 10b5-1 plan
SELL
$32K
1,416 sh
Mar 31, 2026
Apr 2, 2026
traded Mar 31, 2026
+2d
SEC Form 4

Evidence

51
ZR
Zagari RaffaeleDirector
SBLKStar Bulk Carriers Corp.
Open-market sale
SELL$2.62B
11.5K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

38
DZ
Davis ZachEVP & CFO
LNGCheniere Energy, Inc.
Open-market sale
SELL$8.70M
29.0K sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

38
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$186K
5,985 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

35
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$26K
819 sh
Mar 23, 2026Apr 1, 2026
traded Mar 23, 2026
+9dSEC Form 4

Evidence

35
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$8,857
286 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

34
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$62K
1,984 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

34
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$91K
2,927 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

32
BJ
Buonanno Franck JeanVice-President, Global Sales
LAESSEALSQ Corp
Open-market sale · 10b5-1 plan
SELL$24K
10.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

32
PK
Puylaert KevinChief Sales Officer
SOPHSOPHiA GENETICS SA
Open-market sale
SELL$14.13
3 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$5.02M
59.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

27
CB
Cree BrianPresident & Interim CEO
VTSVitesse Energy, Inc.
Open-market sale
SELL$1.31M
70.1K sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

27
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$11K
364 sh
Mar 26, 2026Apr 1, 2026
traded Mar 26, 2026
+6dSEC Form 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.65M
19.5K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

26
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$291K
2,968 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

26
SE
Sabar Karimah EsDirector
CAPRCAPRICOR THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$1.85M
61.3K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

26
ZY
Zeng YanChief Financial Officer
ATHMAutohome Inc.
Open-market sale
SELL$12K
2,704 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

26
XB
Xiang BiboChief Technology Officer
ATHMAutohome Inc.
Open-market sale
SELL$5,314
1,240 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

24
CB
Cree BrianPresident & Interim CEO
VTSVitesse Energy, Inc.
Open-market sale
SELL$926K
50.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

24
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$619K
7,232 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

24
RB
Read BrianChief Financial Officer
SERVServe Robotics Inc. /DE/
Open-market sale
SELL$10K
1,263 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

23
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$247K
2,532 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

23
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$995
32 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

22
SE
Sabar Karimah EsDirector
CAPRCAPRICOR THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$1.67M
53.7K sh
Apr 1, 2026Apr 1, 2026
traded Apr 1, 2026
+0dSEC Form 4

Evidence

21
YT
Yaacobi TalDirector
VLNValens Semiconductor Ltd.
Open-market sale
SELL$1,554
1,400 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

20
MI
Mat IshbiaDirector, President and CEO, 10% Owner
UWMCUWM Holdings Corp
Open-market sale · 10b5-1 plan
SELL$3.55M
1.00M sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

19
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$196K
6,710 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

19
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.72M
21.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

16
MI
Mat IshbiaDirector, President and CEO, 10% Owner
UWMCUWM Holdings Corp
Open-market sale · 10b5-1 plan
SELL$3.63M
1.00M sh
Apr 1, 2026Apr 1, 2026
traded Apr 1, 2026
+0dSEC Form 4

Evidence

14
UC
Ugwumba Chidozie10% Owner
CLNNClene Inc.
Open-market sale
SELL$21K
4,278 sh
Apr 1, 2026Apr 1, 2026
traded Apr 1, 2026
+0dSEC Form 4

Evidence

12
BA
Brady James AloysiusDirector
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$60K
10.8K sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

12
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$24K
790 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$119K
1,485 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$196K
2,366 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$65K
800 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$109K
1,390 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

8
BC
Bird Justin ChristopherExecutive Vice President
SRESEMPRA
Open-market sale · 10b5-1 plan
SELL$109K
1,128 sh
Apr 1, 2026Apr 1, 2026
traded Apr 1, 2026
+0dSEC Form 4

Evidence

8
YS
Yi StevenDirector, See Remarks
MAXMediaAlpha, Inc.
Open-market sale · 10b5-1 plan
SELL$37K
4,000 sh
Apr 1, 2026Apr 1, 2026
traded Apr 1, 2026
+0dSEC Form 4

Evidence

3
YS
Yi StevenDirector, See Remarks
MAXMediaAlpha, Inc.
Open-market sale · 10b5-1 plan
SELL$37K
4,000 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence